At-home spaced transcranial direct current stimulation for treatment-resistant depression
Official title: Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study
Run by University of California, San Diego · NCT07217223 · Data updated 2026-11-12
This will test whether a two-week program of at-home spaced transcranial direct current stimulation (tDCS) can help people with treatment-resistant depression who have not improved on antidepressants.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | University of California, San Diego Academic / other |
| Locations | 1 site (San Diego, California) |
| Status | Recruiting |
| Started | September 27, 2025 |
| Main results expected | October 7, 2026 |
| Study ends | March 1, 2027 |
| Registry record updated | September 15, 2026 |
| Trial ID | NCT07217223 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–85 with diagnosed major depressive disorder and MADRS ≥20 who have a documented inadequate response to antidepressant treatment (ATHF ≥3 or at least two inadequate/intolerant trials), are safe for TMS, and have a stable internet connection and compatible device are ideal candidates.
✕Probably not a fit
People with a history of bipolar disorder, psychosis, significant borderline personality disorder, major comorbid OCD/PTSD, current moderate-to-severe substance use disorder, or those unable to attend four in-person visits in San Diego or lacking reliable internet/device access are unlikely to benefit from or be eligible for this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-arm, open-label feasibility and safety study asks participants with treatment-resistant major depressive disorder to self-administer tDCS at home under live remote supervision. Treatment is delivered over two weeks with weekday sessions consisting of five 20-minute stimulations each day, spaced by ~20-minute intervals for about three hours daily. Pre- and post-treatment neurophysiological biomarker sessions and clinical mood measures are collected, and four required in-person appointments occur at UCSD in San Diego. The study will track safety, tolerability, feasibility of home delivery, and changes in mood and brain activity before, during, and after the intervention.
Why it matters
Potential benefit: If successful, this could offer an effective, lower-burden home treatment option for people whose depression has not responded to standard antidepressants.
How similar studies have gone: Prior tDCS studies for depression and some small home-based tDCS programs have shown mixed but promising results for symptom improvement and feasibility, though the intensive spaced multi-session daily protocol is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. People between the ages of 18 and 85 at the time of screening. 2. Currently diagnosed with Major Depressive Disorder (MDD) as measured by the MINI and a MADRS score of ≥ 20. 3. Safe for TMS as measures by the TMS Adult Safety Screening (TASS). 4. Medical records confirming a history of failing to achieve clinical response to an adequate antidepressant trial as defined an Antidepressant Treatment History Form (ATHF) score ≥ 3 or ) or shown intolerance to at least two inadequate trials (score 1 or 2), without psychiatric illness due to a general medical condition. 5. Stable internet connection and a device compatible with Microsoft Teams. Exclusion Criteria: 1. History of psychotic or bipolar disorder or depression with psychotic features; 2. Significant borderline personality disorder; 3. Significant comorbid obsessive-compulsive or post-traumatic stress: 4. Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal; 5. Clinically significant suicidality disorder; 6. Chronic depression (defined as of over 5 years duration); 7. Pregnancy or lactation, lack of adequate birth control in women of childbearing age; 8. History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma with persistent symptoms; 9. Unstable medical illness; 10. Contraindication to receiving tDCS (e.g., ferromagnetic implant, history of seizure, known brain lesion); 11. History of TMS (greater than 15 sessions) without a clinically meaningful response.; History of ketamine (greater than 4 sessions) without a clinically meaningful response; 12. Require a benzodiazepine with a dose \> lorazepam 2 mg/day; 13. dermatological conditions contraindicating tDCS; 14. Non-correctable sensory impairments; 15. Inability to consent or participate as an outpatient
Where it's running
-
UCSD Interventional Psychiatry
San Diego, California, United States Recruiting
Study contacts
- Study coordinator: Interventional Psychiatry
- Email: iptrials@health.ucsd.edu
- Phone: 858-966-5832
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
French Minds: a French, Multimodal Cohort Study of Severe Psychiatric Disorders and Healthy Controls
This study tests whether people with mood, psychotic, or autism disorders can be grouped into more similar subtypes based on social withdrawal and anhedonia, across ages 15 to 60.
-
Cannabidiol Oil as an Add-on for Treatment-Resistant Major Depression
This study tests whether full-spectrum CBD oil added to standard antidepressants can help adults with treatment-resistant major depression.
-
Accelerated bilateral DMPFC iTBS for major depression
This study tests whether a fast, multiple-daily session brain stimulation approach can help adults with major depressive disorder who have not fully benefited from standard antidepressants.
-
Ketogenic Diet with Accelerated Brain Stimulation for Treatment‑Resistant Depression
This study tests whether adding a ketogenic diet to a personalized accelerated brain stimulation treatment helps reduce depression symptoms in adults with treatment‑resistant depression.
-
Electroconvulsive therapy combined with transcranial magnetic stimulation for treatment-resistant depression
This will test whether giving a short burst of intermittent theta-burst magnetic stimulation (iTBS) just before electroconvulsive therapy helps adults with treatment-resistant major depressive disorder by lowering the energy needed to trigger a therapeutic seizure.
-
Exercise priming before rTMS (iTBS) for difficult-to-treat depression
This will test whether adding a 4-week structured exercise program before and during intermittent theta-burst stimulation (iTBS) helps physically inactive adults with treatment-resistant depression feel better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.